NewAmsterdam reports Q2 net loss of $64.1M; CHMP recommends EU approval for obicetrapib

NewAmsterdam Pharma Co N.V.

2026-Q2 EPS reported -$0.92 revenue$6,741,000

CHMP positive opinion for obicetrapib monotherapy and FDC with ezetimibe; EC decision expected later 2026.
Cash, cash equivalents and marketable securities $678.3M at June 30, 2026, down from $728.9M at Dec 31, 2025.
Net loss $64.1M in Q2 2026 vs $17.4M in Q2 2025; revenue $3.7M vs $19.1M (prior year included $16.1M Menarini milestone).
PREVAIL CVOT interim analysis planned for 4Q2026, result in 1Q2027; RUBENS Phase 3 topline data expected by year-end 2026.
R&D expenses $41.7M (up from $27.5M) driven by clinical trial progression; SG&A $26.9M (down from $27.3M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.